Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1006 · 1 trial · 1 indication
An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.
An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.
| Arm | Type | Description |
|---|---|---|
| Panel A: MK-1006 15/30/45 | EXPERIMENTAL | Participants received a single rising dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods. |
| Panel B: MK-1006 60/80/60 fed | EXPERIMENTAL | Participants received a single rising dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods. |
| Panel C: MK-1006 100/140/170 | EXPERIMENTAL | Participants received a single rising dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods. |
| Name | Type | Description |
|---|---|---|
| MK-1006 | DRUG | MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C. |
| Placebo | DRUG | Matching placebo to MK-1006 in a single oral dose |
Inclusion Criteria: * Japanese male or female between 20 to 64 years of age * Diagnosis of type 2 diabetes * Patient is being treated with diet and exercise alone or single oral anti-hyperglycemic agent Exclusion Criteria: * Subject has a history of type 1 diabetes mellitus * Subject has a clinic...
MK-1006 is an investigational small molecule being developed for Type 2 Diabetes Mellitus and non-insulin-dependent diabetes mellitus. It is in Phase 1 clinical development and is not approved by the FDA. The drug is being studied for its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with these conditions.
MK-1006 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus and non-insulin-dependent diabetes mellitus.
MK-1006 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, one involving 25 patients with Type 2 Diabetes Mellitus and another involving 24 Japanese patients with non-insulin-dependent diabetes mellitus.
MK-1006 has completed two Phase 1 clinical trials. The first, NCT00757601, studied the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-1006 in 25 patients with Type 2 Diabetes Mellitus. The second, NCT00791661, was a single-dose study in 24 Japanese patients with non-insulin-dependent diabetes mellitus.
Yes, MK-1006 and MK1006 refer to the same investigational drug. Clinical trial NCT00757601 is titled 'A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)', confirming that both names are used interchangeably for this compound.